The Rutgers scientists named their new antibiotic TXA709. The drug is unique in that it kills MRSA bacteria by inhibiting the function of FtsZ, the protein that allows the bacteria to divide and survive.
“This is important because even though TXA709 is effective on its own in treating MRSA, combining it with cefdinir — used to treat a wide range of bacterial infections like strep throat, pneumonia, bronchitis and middle ear and sinus infections — makes it even more efficacious, while also significantly reducing the potential for the MRSA bacteria to become resistant in the future,” said study co-author Daniel Pilch, PhD.
Clinical trials to assess the safety and effectiveness of TXA709 in humans are expected to begin during the first half of 2017.
More articles on staph:
Oklahoma researchers find new way to fight MRSA
Researchers identify how MRSA spreads within the body
Antarctic sponge may hold key to eliminating MRSA
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
